Brief: Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities
BRIEF-Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities Oct 1 (Reuters) - Foghorn Therapeutics Inc. FHTX.O:
FOGHORN THERAPEUTICS PROVIDES UPDATE ON FHD-909 AND STRATEGIC PRIORITIES
FOGHORN THERAPEUTICS PROVIDES UPDATE ON FHD-909 AND STRATEGIC PRIORITIES
FOGHORN THERAPEUTICS - CO AND LILLY WILL NOT ADVANCE FHD-909 OR SELECTIVE SMARCA2 DEGRADER PROGRAM
FOGHORN THERAPEUTICS - TO FOCUS RESOURCES ON WHOLLY OWNED PIPELINE INCLUDING EP300 AND CBP DEGRADERS
FOGHORN THERAPEUTICS - EXPECTS CASH RUNWAY INTO SECOND HALF OF 2029 WITH 40% WORKFORCE REDUCTION
FOGHORN THERAPEUTICS - TO REDUCE WORKFORCE BY ABOUT 40% AND ALIGN OPERATING STRUCTURE
FOGHORN THERAPEUTICS: ALSO NOT BE ADVANCING SELECTIVE SMARCA2 DEGRADER PROGRAM, COMPANIES DO NOT ANTICIPATE FURTHER COLLABORATION ACTIVITIES
Source text: ID:nGNXbVFGx0
Further company coverage: FHTX.O
((Reuters.Briefs@thomsonreuters.com;;))